News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Farallon Capital Management, L.L.C., and its affiliated investment partnerships, the Farallon Funds, have disclosed a beneficial ownership of 13,989,010 shares of Exelixis, Inc. (EXEL). This stake represents 5.6% of Exelixis' outstanding common stock and has an approximate net investment cost of $308,124,978. The information …
This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold Exelon Corporation (1EXC) stocks. It details various ETFs, their market value of Exelon holdings, weight percentage, issuer, management style, expense ratio, assets under management (AUM), current price, change, relative volume, and …
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Exelon (EXC) is back in focus after its Commonwealth Edison unit restored power to more than 80% of customers affected by severe storms …
Sharemaestro market context Price below Trend Line 52 weeks -2.6%Exelixis (EXEL) reported its Q2 2026 earnings, with total revenues reaching $628.7 million, a 10.6% increase year-over-year, driven by cabozantinib sales. The company updated its full-year 2026 revenue guidance downwards due to a more gradual sales ramp in the neuroendocrine tumor indication but reduced …
Annex Advisory Services LLC has acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL), purchasing 25,918 shares valued at approximately $1.41 million during the second quarter. This investment comes as Exelixis reported strong quarterly earnings, surpassing EPS expectations, though revenue slightly missed analyst estimates. Despite …
Argus has lowered its target price for Exelixis Inc. (EXEL) to $56.00, while the current price stands at $50.44. Exelixis is a biopharmaceutical company focused on discovering, developing, and commercializing cancer treatments.
Exelixis director Mary Beckerle sold 9,812 shares of the company's common stock for over $526,000, executed under a Rule 10b5-1 trading plan. This transaction leaves her with 16,079 beneficially owned shares, including RSUs. The sale occurred as Exelixis's stock saw a recent decline but …
Exelixis (NASDAQ:EXEL) Director Mary Beckerle sold 9,812 shares of company stock, valued at $526,511.92, under a pre-arranged Rule 10b5-1 trading plan. This transaction reduced her ownership by 37.9% to 16,079 shares. The biotechnology company recently reported strong quarterly earnings, beating analyst estimates with $0.91 …
Exelixis director Mary C. Beckerle sold 9,812 shares of common stock on August 10, 2026, at a weighted average price of $53.66 per share, under a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Beckerle's holdings consist of 16,079 shares, which are to be …
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have disclosed a beneficial ownership of 11,023,943 shares of Exelixis, Inc. common stock, representing 4.39% of the class. The filing indicates shared voting power over 10,935,221 shares and shared dispositive power over all 11,023,943 …
SueWallSt is investigating potential securities claims against Exelixis (NASDAQ: EXEL) following a reduction and narrowing of its full-year 2026 revenue guidance. The company's shares declined after it cited a slower-than-expected ramp in its neuroendocrine-tumor business, contradicting earlier reiterations of its financial outlook. Shareholders who …
CHICAGO, August 11, 2026--(BUSINESS WIRE)--The Exelon Foundation has added two new companies to its Climate Change Investment Initiative (2c2i) portfolio: Public Grid and Buckstop. The investments reflect Exelon's commitment to supporting solutions that improve affordability, make better use of resources and contribute to a …
Sharemaestro market context Price below Trend Line 52 weeks -2.6%The Exelon Foundation has invested in Public Grid and Buckstop through its Climate Change Investment Initiative (2c2i). Public Grid connects residents to energy-saving programs through multifamily housing, aiming to reduce costs and promote efficient energy use. Buckstop focuses on recovering value from existing materials …
Exelon's MidAtlantic utilities are facing challenges in meeting the increasing demand for power from data centers, an issue that is causing investor concern. This report from Morningstar analyst Andrew Bischof highlights the difficulties for the pure-play electric and gas transmission and distribution utility. Previous …
Levi & Korsinsky, LLP has announced an investigation into Exelixis (EXEL) after the company reiterated its full-year 2026 financial guidance on May 5, 2026, only to lower and narrow its revenue outlook weeks later, causing a stock decline. The investigation focuses on whether Exelixis …
This article reports on an SEC Form 144 filing by Exelixis, Inc. (EXEL) on August 10, 2026. The filing indicates a proposed sale of 9,812 shares of common stock with an aggregate market value of $526,496.22, acquired on May 29, 2026, through a restricted …
Exelon Corp. (EXC) stock fell 2.43% to $44.50 on Monday, underperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average also decline. The company's shares closed 12.14% below their 52-week high of $50.65.
This article analyzes Exelixis Inc. (NASDAQ: EXEL) using AI models to provide institutional trading strategies. It highlights a weak near-term sentiment but strong long-term outlook, with a significant 26.9:1 risk-reward setup. Three distinct strategies—Position Trading, Momentum Breakout, and Risk Hedging—are detailed, alongside multi-timeframe signal …
Assenagon Asset Management S.A. significantly increased its stake in Exelon Corporation by 133.9% in the second quarter, bringing its total holdings to 505,564 shares valued at $23.57 million. Despite this, institutional investors collectively own 80.92% of Exelon, while analyst sentiment remains cautious with a …
This article provides current stock news for Exelon Corp (EXC), an electric utility company. As of August 10th, EXC closed at $44.855, showing a slight increase, with a market capitalization of $46.29 billion. The latest news highlights that GE Vernova Inc stock (GEV) experienced …
EXELIXIS ($EXEL) announced its Q2 2026 earnings, reporting $0.91 per share, which surpassed estimates. However, the company's revenue of $628.69 million fell short of expectations. Following the announcement, the stock experienced a 5.23% decline.
Exelixis, Inc.'s average stock price target has been raised from $52.25 to $52.62 by 16 analysts, suggesting a potential 7% downside based on the August 5 closing price. Despite the raised target implying a decrease, the consensus rating for EXEL remains a "Buy" from …
Exelixis reported Q4 2025 revenues of $599M, primarily driven by a 6% year-over-year increase in U.S. CABOMETYX sales to $547M, with full-year 2025 U.S. CABOMETYX revenue reaching $2.12B, up 17% year-over-year. The company is preparing for a potential late 2026 launch of zanzalintinib for …
Quantinno Capital Management LP significantly increased its stake in Exelixis, Inc. by 44.3% in the first quarter, now holding 115,592 shares valued at approximately $4.96 million. This increase occurred despite mixed analyst ratings and recent insider selling. Exelixis reported strong second-quarter adjusted earnings but …
Bank of America Corp DE reduced its stake in Exelon Corporation by 19.8% in the first quarter, selling 1.57 million shares and retaining 6.34 million shares valued at $310.6 million. Despite this, Exelon reported a 10% year-over-year revenue increase to $5.97 billion in Q2 …
Leerink Partners has downgraded its rating for Exelixis Inc (EXEL.O) from "Outperform" to "Market Perform." This change indicates a revised outlook on the pharmaceutical company's stock performance. The update was reported by Reuters.
Exelixis (EXEL) saw its stock drop 6.7% after cutting its 2026 revenue outlook to $2.50 billion–$2.55 billion. This revision came despite solid Q2 earnings and is attributed to slower growth in the neuroendocrine tumor indication and continued heavy investment in its zanzalintinib pipeline and …
EXELIXIS, INC. reported strong second-quarter 2026 results with revenue of $628.69M and diluted EPS of $0.82, showing significant year-over-year growth due to increased product demand and price gains. Key drivers included CABOMETYX sales, progress in pipeline development with zanzalintinib, and expanded clinical trials. The …
Exelixis Inc (EXEL) reported strong financial results for Q2 2026, surpassing analyst expectations with total revenues of $628.7 million and a GAAP diluted EPS of $0.82. The biopharmaceutical company, known for its cancer treatments like cabozantinib, updated its fiscal year 2026 guidance, projecting total …
Search by ticker symbol or company name and select a result to open its chart.